Imaging the Neurochemistry of Drug Addiction With PET

Smoking Clinical Trial

Official title:

Imaging the Neurochemistry of Drug Addiction With PET

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02817698
• Other study ID #: 1604017594
• Secondary ID: 1R01DA038709-01A
• Status: Recruiting
• Phase: Early Phase 1
• Start date: November 29, 2017
• Est. completion date: September 2024

Study information

• Verified date: October 2023
• Source: Yale University
• Contact: Kelly Cosgrove, PhD
• Phone: 203-737-6969
• Email: kelly.cosgrove[@]yale.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators' project has two overarching goals. 1) The investigators will use newly developed positron emission tomography (PET) technology to investigate the dopaminergic neurochemistry of drugs of abuse including marijuana, traditional cigarettes, and cocaine, and 2) The investigators will extend PET technology to an additional neurotransmitter system - namely, the opioid-ergic system, using the same drugs of abuse.

Description:

Aim 1. To examine the magnitude, location and timing of drug-induced dopamine release. 1. Tobacco smokers (n=20) will be imaged with [11C]raclopride PET, after overnight abstinence from tobacco. Subjects will smoke their preferred brand of cigarette during the PET scan. 2. Marijuana smokers (n=20) will be imaged with [11C]raclopride PET, after overnight abstinence from marijuana. Subjects will smoke a marijuana cigarette during the PET scan. 3. Cocaine users (n=20) will be imaged with [11C]raclopride PET, after overnight abstinence from cocaine. Subjects will be administered cocaine during the PET scan. Aim 2. To examine the magnitude, location and timing of drug-induced beta-endorphin release. *The Investigators will attempt to use the same subjects from Aim 1 for Aim 2. 1. Tobacco smokers (n=20) will be imaged with [11C]carfentanil PET, after overnight abstinence from tobacco. Subjects will smoke their preferred brand of cigarette during the PET scan. 2. Marijuana smokers (n=20) will be imaged with [11C]carfentanil PET, after overnight abstinence from marijuana. Subjects will smoke a marijuana cigarette during the PET scan. 3. Cocaine users (n=20) will be imaged with [11C]carfentanil PET, after overnight abstinence from cocaine. Subjects will be administered cocaine during the PET scan.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• General Inclusion Criteria:

1. Men and women, aged 18-55 years

2. Able to read and write English and give voluntary written informed consent

3. Not treatment seeking or using treatment medications Tobacco Smokers

1. Have a Fagerström Test for Nicotine Dependence (FTND) rating of at least 3.

2. Have been using at least 7 cigarettes per day for at least 1 year

3. Carbon monoxide levels > 10 ppm during intake evaluation

4. Urine cotinine levels of > 150 ng/mL during intake evaluation

5. Are not current users of marijuana or other illicit drugs Marijuana Smokers

1. Meet DSM-V criteria for cannabis use disorder based on the structured clinical interview diagnostic (SCID) or regular cannabis use of >5 times/week

2. Test positive for THC

3. Have been smoking cannabis on a regular basis for > 1 year Cocaine Users

1. DSM-V criteria for Cocaine Abuse or Dependence

2. Recent street cocaine use in excess of amounts to be administered in the current study

3. Intravenous and/or smoked (crack/ freebase) use

4. Positive urine toxicology screen for cocaine

Exclusion Criteria:

• 1. Current significant medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology.

2. History of or current neurological or significant psychiatric disorder such as schizophrenia or bipolar disorder (DSM-IV Axis 1).

3. History of significant head trauma. 4. Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive sponge, double barrier [diaphragm or condom plus spermicide], or IUD).

5. Regular or current significant use of any prescription, herbal or illegal psychotropic medications (e.g., antidepressants, antipsychotics, anxiolytics, ecstasy) in the past 6 mo, with no current illegal drug use confirmed by urine toxicology (except for cocaine and marijuana when relevant).

6. Significant substance misuse (including alcohol, and excluding cannabis and marijuana when relevant) that in the PI's determination interferes with the study results or safety of the subject.

7. Have MRI-incompatible implants and other contraindications for MRI, such as a pacemaker, artificial joints, non-removable body piercings, claustrophobia, etc.

8. Subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year.

9. Subjects with current, past or anticipated exposure to radiation in the work place within one year of proposed research PET scans.

10. Subjects with history of IV drug use which would prevent venous access for PET tracer injection.

Related Conditions & MeSH terms

• Cannabis
• Smoking
• Substance-Related Disorders

Intervention

Drug:
• cannabis
All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.

Locations

Country	Name	City	State
United States	Connecticut Mental Health Center	New Haven	Connecticut
United States	Yale Magnetic Resonance Research Center	New Haven	Connecticut
United States	Yale PET Center	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in dopamine levels at baseline and after drug of dependence administration as confirmed by PET images.	PET images will be obtained in dependent subjects at baseline and after drug of dependence administration. Change in DA levels will be determined by change in binding potential of raclopride.	90 minute PET scan acquisition. Drug of dependence will be given at -35 mins
Primary	Change in beta endorphin levels at baseline and after drug of dependence administration as confirmed by PET images.	PET images will be obtained in dependent subjects at baseline and after drug of dependence administration. Change in beta endorphin levels will be determined by change in binding potential of carfentanil.	120 minute PET scan acquisition. Drug of dependence will be given at -35 mins